BG Medicine Performance
| BGMDDelisted Stock | USD 0.0002 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 8.24, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BG Medicine will likely underperform. BG Medicine today owns a risk of 0.0%. Please confirm BG Medicine coefficient of variation and the relationship between the information ratio and rate of daily change , to decide if BG Medicine will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BG Medicine has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound primary indicators, BG Medicine is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Total Cashflows From Investing Activities | 13 K |
BGMD |
BG Medicine Relative Risk vs. Return Landscape
If you would invest 0.02 in BG Medicine on January 17, 2024 and sell it today you would earn a total of 0.00 from holding BG Medicine or generate 0.0% return on investment over 90 days. BG Medicine is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than BGMD, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BG Medicine Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BG Medicine's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BG Medicine, and traders can use it to determine the average amount a BG Medicine's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BGMD |
Based on monthly moving average BG Medicine is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BG Medicine by adding BG Medicine to a well-diversified portfolio.
BG Medicine Fundamentals Growth
BGMD Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BG Medicine, and BG Medicine fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BGMD Pink Sheet performance.
| Return On Equity | -9.03 | ||||
| Return On Asset | -0.76 | ||||
| Operating Margin | (2.86) % | ||||
| Current Valuation | 545.97 K | ||||
| Shares Outstanding | 11.37 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.35 X | ||||
| Revenue | 1.57 M | ||||
| EBITDA | (4.39 M) | ||||
| Cash And Equivalents | 1.52 M | ||||
| Cash Per Share | 0.14 X | ||||
| Debt To Equity | 5.31 % | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (3.67 M) | ||||
| Earnings Per Share | (0.72) X | ||||
| Total Asset | 2.13 M | ||||
| Retained Earnings | (161.49 M) | ||||
| Current Asset | 1.95 M | ||||
| Current Liabilities | 1.18 M | ||||
About BG Medicine Performance
To evaluate BG Medicine Pink Sheet as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when BG Medicine generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare BGMD Pink Sheet's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand BG Medicine market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents BGMD's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.BG Medicine, Inc. engages in the development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG MEDICINE operates under Medical Instruments Supplies classification in the United States and is traded on PNK Exchange. It employs 5 people.Things to note about BG Medicine performance evaluation
Checking the ongoing alerts about BG Medicine for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BG Medicine help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BG Medicine is not yet fully synchronised with the market data | |
| BG Medicine has some characteristics of a very speculative penny stock | |
| BG Medicine has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.57 M. Net Loss for the year was (5.3 M) with profit before overhead, payroll, taxes, and interest of 1.06 M. | |
| BG Medicine currently holds about 1.52 M in cash with (3.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.14, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing BG Medicine's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BG Medicine's stock is overvalued or undervalued compared to its peers.
- Examining BG Medicine's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BG Medicine's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BG Medicine's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BG Medicine's pink sheet. These opinions can provide insight into BG Medicine's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in BGMD Pink Sheet
If you are still planning to invest in BG Medicine check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BG Medicine's history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Stocks Directory Find actively traded stocks across global markets |